Effect of HLA-B27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patients
Background: Tumor necrosis factor-alpha inhibitors (infliximab) have changed the therapeutic approach to ankylosing spondylitis (AS). Body mass index (BMI) and HLA-B27 status may affect the response to infliximab. Methods: One hundred and seventy AS patients with active disease were enrolled in the...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2018;volume=13;issue=1;spage=33;epage=37;aulast=Al-Osami |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849306323783516160 |
|---|---|
| author | Mohammed Hadi Al-Osami Ekhlas Khalid Hameed Ali Mohammed Al-Hamadani |
| author_facet | Mohammed Hadi Al-Osami Ekhlas Khalid Hameed Ali Mohammed Al-Hamadani |
| author_sort | Mohammed Hadi Al-Osami |
| collection | DOAJ |
| description | Background: Tumor necrosis factor-alpha inhibitors (infliximab) have changed the therapeutic approach to ankylosing spondylitis (AS). Body mass index (BMI) and HLA-B27 status may affect the response to infliximab.
Methods: One hundred and seventy AS patients with active disease were enrolled in the study. Age, sex, disease duration, HLA-B27 status, and other demographics were obtained. Patients were classified according to their BMI to three groups clinical response was monitored using Bath AS disease activity index, at the time of initiation of treatment and 6 months later. Clinical response was defined as BASDAI50.
Results: At baseline, all the groups were comparable. The median BMI of the responders was 25.4 kg/m2 while for the nonresponders it was 27 kg/m2. The normal weight and overweight AS patients have achieved the BASDAI 50 response after 6 months of infliximab treatment (P < 0.001) while the obese AS patients fail to achieve this response by infliximab alone and they need another drug (nonsteroidal anti-inflammatory drugs). The response was higher in HLA-B27 positive patients (42.5%) compared to the HLA-B27 negative patients (29%), the difference, however, was statistically insignificant.
Conclusion: Obese AS patients are less likely to achieve a response to infliximab than normal weight AS patients. |
| format | Article |
| id | doaj-art-2e6203337416416bbfb04d921b56eace |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-2e6203337416416bbfb04d921b56eace2025-08-20T03:55:07ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012018-01-01131333710.4103/injr.injr_89_17Effect of HLA-B27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patientsMohammed Hadi Al-OsamiEkhlas Khalid HameedAli Mohammed Al-HamadaniBackground: Tumor necrosis factor-alpha inhibitors (infliximab) have changed the therapeutic approach to ankylosing spondylitis (AS). Body mass index (BMI) and HLA-B27 status may affect the response to infliximab. Methods: One hundred and seventy AS patients with active disease were enrolled in the study. Age, sex, disease duration, HLA-B27 status, and other demographics were obtained. Patients were classified according to their BMI to three groups clinical response was monitored using Bath AS disease activity index, at the time of initiation of treatment and 6 months later. Clinical response was defined as BASDAI50. Results: At baseline, all the groups were comparable. The median BMI of the responders was 25.4 kg/m2 while for the nonresponders it was 27 kg/m2. The normal weight and overweight AS patients have achieved the BASDAI 50 response after 6 months of infliximab treatment (P < 0.001) while the obese AS patients fail to achieve this response by infliximab alone and they need another drug (nonsteroidal anti-inflammatory drugs). The response was higher in HLA-B27 positive patients (42.5%) compared to the HLA-B27 negative patients (29%), the difference, however, was statistically insignificant. Conclusion: Obese AS patients are less likely to achieve a response to infliximab than normal weight AS patients.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2018;volume=13;issue=1;spage=33;epage=37;aulast=Al-OsamiAnkylosing spondylitisbody mass indexHLA-B27infliximab |
| spellingShingle | Mohammed Hadi Al-Osami Ekhlas Khalid Hameed Ali Mohammed Al-Hamadani Effect of HLA-B27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patients Indian Journal of Rheumatology Ankylosing spondylitis body mass index HLA-B27 infliximab |
| title | Effect of HLA-B27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patients |
| title_full | Effect of HLA-B27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patients |
| title_fullStr | Effect of HLA-B27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patients |
| title_full_unstemmed | Effect of HLA-B27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patients |
| title_short | Effect of HLA-B27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patients |
| title_sort | effect of hla b27 status and body mass index on the clinical response to infliximab in ankylosing spondylitis patients |
| topic | Ankylosing spondylitis body mass index HLA-B27 infliximab |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2018;volume=13;issue=1;spage=33;epage=37;aulast=Al-Osami |
| work_keys_str_mv | AT mohammedhadialosami effectofhlab27statusandbodymassindexontheclinicalresponsetoinfliximabinankylosingspondylitispatients AT ekhlaskhalidhameed effectofhlab27statusandbodymassindexontheclinicalresponsetoinfliximabinankylosingspondylitispatients AT alimohammedalhamadani effectofhlab27statusandbodymassindexontheclinicalresponsetoinfliximabinankylosingspondylitispatients |